IART
INTEGRA LIFESCIENCES HOLDINGS CORP
$17.77
+1.48%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusSell (13%)
Inst. Holders50 funds
Inst. Value$549.3M
Inst. Activity11 buys / 7 sells
SEC Reports7
Press Releases1
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0000917520·Prev Close $17.51
Recent Activity
Jun 2, 2026
other
Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
<p>PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (N
Jun 1, 2026
Insider
ESSIG STUART was granted 705,468 shares
President and CEO
Jun 1, 2026
Insider
ESSIG STUART was granted 365,297 shares
President and CEO
Jun 1, 2026
Insider
McBreen Michael J. was granted 60,372 shares
EVP & Chief Commercial Officer
May 8, 2026
SEC
Integra LifeSciences reported results from its 2026 Annual Meeting. Stockholders approved a 3,550,000-share increase to
8-K — Impact 2/10
May 5, 2026
SEC
Integra LifeSciences filed a DEFA14A proxy supplement confirming that former CEO Mojdeh Poul will not stand for election
DEFA14A — Impact 3/10
May 5, 2026
SEC
Integra LifeSciences announced that Chairman Stuart Essig has been appointed President and CEO, effective May 1, 2026, r
8-K — Impact 4/10
Inst.
BANK OF AMERICA CORP — ADD
1,414,509 shares ($13.3M)
Price Targets
$17.43
-1.9% upside
Hold
Current $17.77
Low $11.00
Median $15.00
High $27.00
7 analysts
$11.00
$27.00
Analyst Ratings
1Strong Buy
1Buy
8Hold
3Sell
2Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Citigroup | UPGRADE | Sell → Neutral |
| May 6, 2026 | Citigroup | MAINTAIN | Sell → Sell |
| May 6, 2026 | Wells Fargo | MAINTAIN | Equal-Weight → Equal-Weight |
| Apr 15, 2026 | Truist Securities | MAINTAIN | Hold → Hold |
| Apr 15, 2026 | Argus Research | DOWNGRADE | Buy → Hold |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.48 ▼ -8.6% | $0.46 — $0.50 | 8% YoY | 9 |
| Next Q | $0.56 ▼ -4.2% | $0.49 — $0.60 | 4% YoY | 9 |
| Current FY | $2.45 ▲ +4.6% | $2.42 — $2.50 | 10% YoY | 9 |
| Next FY | $2.61 ▲ +1.8% | $2.50 — $2.73 | 7% YoY | 10 |
Latest Reports
NEUTRAL
8-K
2/10
Integra LifeSciences reported results from its 2026 Annual Meeting. Stockholders approved a 3,550,000-share increase to
May 8, 2026
NEUTRAL
DEFA14A
3/10
Integra LifeSciences filed a DEFA14A proxy supplement confirming that former CEO Mojdeh Poul will not stand for election
May 5, 2026
NEUTRAL
Press
4/10
Integra LifeSciences appointed Chairman Stuart Essig as President and CEO, effective May 1, 2026, replacing Mojdeh Poul
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $97.2M | — |
| Rubric Capital Management LP | $73.0M | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $34.7M | — |
| MORGAN STANLEY | $33.8M | — |
| FULLER & THALER ASSET | $33.2M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | ESSIG STUART | A | $0.00 |
| Jun 1, 2026 | ESSIG STUART | A | $0.00 |
| Jun 1, 2026 | McBreen Michael | A | $0.00 |
| Jun 1, 2026 | McBreen Michael | A | $0.00 |
| May 9, 2026 | BRADLEY KEITH | F | $12.3K |
50 institutional holders with $549.3M total value (58,280,477 shares) as of 2026-Q1. Top holders: BlackRock,, Rubric, VANGUARD. Net buying activity: 11 institutions added/increased vs 7 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10,319,169 | $97.2M | 17.7% | — |
| 2 | Rubric Capital Management LP | 7,753,934 | $73.0M | 13.3% | — |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 3,686,637 | $34.7M | 6.3% | — |
| 4 | MORGAN STANLEY | 3,584,155 | $33.8M | 6.1% | — |
| 5 | FULLER & THALER ASSET MANAGEMENT, INC. | 3,529,404 | $33.2M | 6.1% | — |
| 6 | Invesco Ltd. | 3,485,603 | $32.8M | 6.0% | — |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 2,890,824 | $27.2M | 5.0% | — |
| 8 | STATE STREET CORP | 2,886,556 | $27.2M | 5.0% | — |
| 9 | DIMENSIONAL FUND ADVISORS LP | 2,774,988 | $26.1M | 4.8% | — |
| 10 | Neuberger Berman Group LLC | 2,115,255 | $19.9M | 3.6% | ADD +35.3% |
| 11 | GOLDMAN SACHS GROUP INC | 1,876,750 | $17.7M | 3.2% | — |
| 12 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,612,145 | $15.2M | 2.8% | — |
| 13 | BANK OF AMERICA CORP /DE/ | 1,414,509 | $13.3M | 2.4% | ADD +71.4% |
| 14 | WELLINGTON MANAGEMENT GROUP LLP | 1,300,290 | $12.2M | 2.2% | — |
| 15 | GLENMEDE TRUST CO NA | 984,686 | $9.3M | 1.7% | ADD +27.4% |
| 16 | Allianz Asset Management GmbH | 889,604 | $8.4M | 1.5% | ADD +36.7% |
| 17 | BALYASNY ASSET MANAGEMENT L.P. | 694,076 | $6.5M | 1.2% | DOUBLED +409.3% |
| 18 | CITADEL ADVISORS LLC | 476,701 | $4.5M | 0.8% | — |
| 19 | DEUTSCHE BANK AG\ | 446,530 | $4.2M | 0.8% | — |
| 20 | CANADA PENSION PLAN INVESTMENT BOARD | 434,900 | $4.1M | 0.7% | ADD +79.2% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 825,101 | 1,414,509 | +71.4% | $13.3M | 2026-Q1 |
| GLENMEDE TRUST CO NA | ADD | 772,912 | 984,686 | +27.4% | $9.3M | 2026-Q1 |
| Allianz Asset Management GmbH | ADD | 650,647 | 889,604 | +36.7% | $8.4M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 136,285 | 694,076 | +409.3% | $6.5M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 433,388 | 252,904 | -41.6% | $2.4M | 2026-Q1 |
| ExodusPoint Capital Management, LP | DOUBLED | 101,446 | 242,399 | +138.9% | $2.3M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | TRIM | 196,264 | 99,864 | -49.1% | $940.7K | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 59,186 | 93,726 | +58.4% | $882.9K | 2026-Q1 |
| EXCHANGE TRADED CONCEPTS, LLC | ADD | 50,973 | 68,050 | +33.5% | $641.0K | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 418 | 53,976 | +12812.9% | $508.5K | 2026-Q1 |
| Brevan Howard Capital Management LP | DOUBLED | 11,222 | 50,317 | +348.4% | $474.0K | 2026-Q1 |
| Amundi | ADD | 10,749 | 19,430 | +80.8% | $183.0K | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | TRIM | 30,411 | 18,455 | -39.3% | $173.8K | 2026-Q1 |
| Verition Fund Management LLC | NEAR_EXIT | 96,054 | 17,116 | -82.2% | $161.2K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 1,181 | 1,596 | +35.1% | $15.0K | 2026-Q1 |
| CWM, LLC | TRIM | 2,647 | 1,275 | -51.8% | $12.0K | 2026-Q1 |
| Rockefeller Capital Management L.P. | TRIM | 1,679 | 1,091 | -35.0% | $10.3K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | NEAR_EXIT | 677 | 32 | -95.3% | $301.00 | 2026-Q1 |
| Neuberger Berman Group LLC | ADD | 1,535,184 | 2,077,180 | +35.3% | $25.8M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 624,080 | 825,101 | +32.2% | $10.2M | 2025-Q4 |
| Allianz Asset Management GmbH | ADD | 433,738 | 650,647 | +50.0% | $8.1M | 2025-Q4 |
| Legal & General Group Plc | ADD | 242,732 | 368,947 | +52.0% | $4.6M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 519,366 | 353,264 | -32.0% | $4.4M | 2025-Q4 |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | 71,906 | 171,288 | +138.2% | $2.1M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 25,120 | 136,285 | +442.5% | $1.7M | 2025-Q4 |
15 unique insiders with 33 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | ESSIG STUART | President and CEO | AWARD | 705,468 | — | — |
| Jun 1, 2026 | ESSIG STUART | President and CEO | AWARD | 365,297 | — | — |
| Jun 1, 2026 | McBreen Michael J. | EVP & Chief Commercial Officer | AWARD | 60,372 | — | — |
| Jun 1, 2026 | McBreen Michael J. | EVP & Chief Commercial Officer | AWARD | 31,909 | — | — |
| May 9, 2026 | BRADLEY KEITH | Director | TAX W/H | 882 | $13.92 | $12.3K |
| May 7, 2026 | SCHADE CHRISTIAN S | Director | AWARD | 17,700 | — | — |
| May 7, 2026 | Lo Renee Wonlai | Director | AWARD | 17,700 | — | — |
| May 7, 2026 | GRAVES JEFFREY A | Director | AWARD | 17,700 | — | — |
| May 7, 2026 | Clay Shaundra | Director | AWARD | 17,700 | — | — |
| May 7, 2026 | BRADLEY KEITH | Director | AWARD | 17,700 | — | — |
| May 7, 2026 | HILL BARBARA B | Director | AWARD | 6,638 | — | — |
| Mar 11, 2026 | Poul Mojdeh | President & CEO | AWARD | 343,393 | — | — |
| Mar 11, 2026 | Mosebrook Jeffrey | SVP, Fin & Princ Acct Officer | TAX W/H | 806 | $9.61 | $7.7K |
| Mar 11, 2026 | McBreen Michael J. | EVP & President, CSS | TAX W/H | 7,247 | $9.61 | $69.6K |
| Mar 11, 2026 | McBreen Michael J. | EVP & President, CSS | AWARD | 92,108 | — | — |
| Mar 11, 2026 | Hutchinson Michael Damon | EVP, Chief Legal Officer & Sec | AWARD | 70,305 | — | — |
| Mar 11, 2026 | DAVIS ROBERT T. JR. | EVP & President, TT | AWARD | 43,350 | — | — |
| Mar 11, 2026 | DAVIS ROBERT T. JR. | EVP & President, TT | TAX W/H | 8,487 | $9.61 | $81.6K |
| Mar 11, 2026 | Veillon-Berteloot Chantal | EVP & CHRO | AWARD | 41,783 | — | — |
| Mar 11, 2026 | Veillon-Berteloot Chantal | EVP & CHRO | TAX W/H | 5,420 | $9.61 | $52.1K |
| Mar 11, 2026 | Knight Lea Daniels | EVP & Chief Financial Officer | TAX W/H | 8,089 | $9.61 | $77.7K |
| Mar 11, 2026 | Knight Lea Daniels | EVP & Chief Financial Officer | AWARD | 111,179 | — | — |
| Mar 11, 2026 | Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | TAX W/H | 861 | $9.61 | $8.3K |
| Mar 11, 2026 | Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | EXERCISE | 18,922 | — | — |
| Mar 11, 2026 | Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | EXERCISE | 2,356 | — | — |
| Mar 11, 2026 | Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | AWARD | 60,865 | — | — |
| Mar 11, 2026 | Mosebrook Jeffrey | SVP, Fin & Princ Acct Officer | AWARD | 15,957 | — | — |
| Mar 10, 2026 | Mosebrook Jeffrey | SVP, Fin & Princ Acct Officer | TAX W/H | 341 | $9.55 | $3.3K |
| Mar 10, 2026 | McBreen Michael J. | EVP & President, CSS | TAX W/H | 2,354 | $9.55 | $22.5K |
| Mar 10, 2026 | DAVIS ROBERT T. JR. | EVP & President, TT | TAX W/H | 687 | $9.55 | $6.6K |
| Mar 10, 2026 | Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | TAX W/H | 601 | $9.55 | $5.7K |
| Mar 10, 2026 | Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL | EXERCISE | 1,216 | — | — |
| Feb 2, 2026 | Hutchinson Michael Damon | EVP, Chief Legal Officer & Sec | AWARD | 89,606 | — | — |
7 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 2 mixed, 3 neutral. Avg impact: 5.1/10.
NEUTRAL
8-K
2/10
Integra LifeSciences reported results from its 2026 Annual Meeting. Stockholders approved a 3,550,00
May 8, 2026
NEUTRAL
DEFA14A
3/10
Integra LifeSciences filed a DEFA14A proxy supplement confirming that former CEO Mojdeh Poul will no
May 5, 2026
NEUTRAL
8-K
4/10
Integra LifeSciences announced that Chairman Stuart Essig has been appointed President and CEO, effe
May 5, 2026
BULLISH
8-K
7/10
Integra LifeSciences reported Q1 2026 adjusted EPS of $0.54, beating the $0.41 consensus by 31.7%, o
May 5, 2026
MIXED
PRESS-RELEASE
6/10
Integra LifeSciences reported Q1 2026 adjusted EPS of $0.54, beating the $0.40 consensus by 35%, on
May 5, 2026
BULLISH
PRESS-RELEASE
8/10
Integra LifeSciences announced a significant earnings beat for Q4 2025, reporting EPS of $0.83 versu
Apr 20, 2026
MIXED
8-K
6/10
Integra LifeSciences reported mixed results for 2025, with full-year revenue up 1.5% but adjusted EP
Feb 26, 2026
Current analyst consensus: Strong Sell (13% buy). Based on 15 analysts: 1 strong buy, 1 buy, 8 hold, 3 sell, 2 strong sell.
Analyst Price Targets
$17.43 mean target
-1.9% upside
Hold (2.90)
$11.00 Low
$27.00 High
| Metric | Value |
|---|---|
| Current Price | $17.77 |
| Target Low | $11.00 |
| Target Mean | $17.43 |
| Target Median | $15.00 |
| Target High | $27.00 |
| # Analysts | 7 |
| Recommendation | Hold (2.90) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.48 | $0.46 | $0.50 | 7.6% | -8.6% | 1↑ 5↓ | $0.4B | 0.5% | 9 |
| Next Q 2026-09-30 |
$0.56 | $0.49 | $0.60 | 3.8% | -4.2% | 2↑ 5↓ | $0.4B | 3.9% | 9 |
| Current FY 2026-12-31 |
$2.45 | $2.42 | $2.50 | 9.8% | +4.6% | 7↑ 0↓ | $1.7B | 2.5% | 9 |
| Next FY 2027-12-31 |
$2.61 | $2.50 | $2.73 | 6.6% | +1.8% | 5↑ 1↓ | $1.7B | 3.3% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.484 | |
| 7d ago | $0.484 | |
| 30d ago | $0.530 | -0.046 |
| 60d ago | $0.524 | -0.040 |
| 90d ago | $0.531 | -0.047 |
4 analyst firms have rated this stock: 1 upgrades, 1 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Citigroup | UPGRADE | Sell | Neutral |
| May 6, 2026 | Citigroup | MAINTAIN | Sell | Sell |
| May 6, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Apr 15, 2026 | Truist Securities | MAINTAIN | Hold | Hold |
| Apr 15, 2026 | Argus Research | DOWNGRADE | Buy | Hold |
| Mar 11, 2026 | Citigroup | MAINTAIN | Sell | Sell |
| Feb 27, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 1 | 1 | 8 | 3 | 2 | 13% | |
| May 1, 2026 | 1 | 1 | 8 | 3 | 3 | 13% | |
| Apr 1, 2026 | 2 | 1 | 7 | 3 | 3 | 19% | |
| Mar 1, 2026 | 2 | 1 | 7 | 4 | 3 | 18% | |
| Feb 1, 2026 | 2 | 1 | 7 | 4 | 3 | 18% | |
| Jan 1, 2026 | 2 | 1 | 7 | 4 | 3 | 18% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
other
Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
<p>PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology
May 8, 2026
other
Integra LifeSciences to Present at the BofA Securities 2026 Health Care Conference
<p>PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology c
May 5, 2026
leadership
Integra LifeSciences Announces Leadership Transition
<p align="center"><em>Stuart Essig Appointed as Integra’s Next President and Chief Executive Officer</em><br><em>Michael McBreen Appointed Chief Comme
May 5, 2026
earnings
Integra LifeSciences Reports First Quarter 2026 Financial Results
<p>PRINCETON, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=oj0jM5sTb4eu5Bv8K11t8mJO4jR3stkaNzpq-lHpJxg
May 5, 2026
earnings_calendar
IART Q1 2026 Earnings Scheduled — 2026-05-05
Apr 20, 2026
earnings
Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026
<p>PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=-QCGNYKwub1UCDkMFXP_QOFfUuKaMdYAMDbQClWq4
Apr 7, 2026
other
Integra LifeSciences Unveils New Real-World Evidence Highlighting PriMatrix® Utilization
Results to be featured at Functional Diabetic Limb Salvage, Society of Advanced Wound Care and American Burn Association Conferences in April <pre>Res
Mar 30, 2026
Enforcement
3:23-cv-20321 PEMBROKE PINES FIREFIGHTERS & POLICE OFFICERS PENSION FUND v. Integra LifeSciences Holdings Corporation et al
Court ruling from United States District Court for the District of New Jersey. Docket: N/A
Feb 26, 2026
earnings_calendar
IART Q4 2025 Earnings Before Market Open — 2026-02-26